CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Percutaneous Electrical Nerve Stimulation (PENS) and Percutaneous Neuromodulation Therapy (PNT) Policy

Defines Blue Cross & Blue Shield of Rhode Island coverage position for PENS/PNT for chronic pain conditions across Commercial and Medicare Advantage products, describes medical necessity criteria, coding guidance, and background evidence summary.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyPercutaneous Electrical Nerve Stimulation (PENS) and Percutaneous Neuromodulation Therapy (PNT) Policy

Policy CodePolicy N/A

Change TypeClarifiedRevised

Effective DateOct 2, 2018

Next Review DateN/A

Key ActionFor Medicare Advantage members, document site of service and performing provider; PENS must be performed in an office, clinic, or hospital outpatient department by a physician or incident to a physician's service.

SourceLink

POLICY UPDATE CHANGES

Medicare Advantage coverage is aligned with CMS guidelines and PENS/PNT is covered when criteria (site, provider, and need for implantation) are met.

Commercial product position states PENS/PNT is not medically necessary due to insufficient evidence.

1Unlisted CPT code specified

Medicare vs CommercialCoverage differentiation

Multiple small trialsEvidence volume

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

This policy defines a mixed coverage stance: for Medicare Advantage members PENS/PNT may be covered when specific Medicare criteria are met (site of service, provider, and need for implantation), while for Commercial products PENS/PNT is considered not medically necessary because the evidence is insufficient. The Medicare Advantage position follows CMS guidelines and covers PENS/PNT when the medical necessity criteria are satisfied.

The evidence base consists primarily of multiple small trials and a limited number of randomized studies. Available trials have methodological limitations (short-term follow-up, unclear or absent blinding), and the highest-quality PENS trial found no difference between active and sham. Overall, evidence is judged insufficient to determine effects on health outcomes for commercial coverage decisions.

Key dates, coverage, evidence, and coding

Effective date2018-10-02

Last review2021-08-18

Coverage differentiationMedicare Advantage may be covered when criteria are met; Commercial — not medically necessary (evidence insufficient)

Evidence volumeMultiple small trials; single randomized trial for PNT; overall evidence insufficient

Unlisted CPT code specifiedUse CPT unlisted procedure, nervous system specific — 64999

Medical-Necessity Criteria

Medically Necessary (Medicare Advantage Plans)

Covered when ALL of the following are met:

ALL of the following

Site of service: Procedure is percutaneous electrical neurostimulation (PENS) or percutaneous neuromodulation therapy (PNT) performed in a physician's office, clinic, or hospital outpatient department
Performing provider: Procedure is performed by a physician or incident to a physician's service
Clinical indication: Chronic condition (eg, back, neck, neuropathy, headache, hyperalgesia, knee osteoarthritis) is effectively controlled by percutaneous stimulation and implantation of electrodes is warranted

Not Medically Necessary (Commercial Product)

Commercial product coverage statement:

Not medically necessary statement: Percutaneous electrical neurostimulation (PENS) or percutaneous neuromodulation therapy (PNT) for the treatment of chronic conditions is considered not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes

Provider Actions

Documentation Required

Site and provider requirement for Medicare Advantage

For Medicare Advantage members, PENS/PNT must be performed in a physician's office, clinic, or hospital outpatient department and must be performed by a physician or incident to a physician's service. Document the site of service and the performing provider in the medical record.

Prior Authorization

Prior authorization

This policy indicates "Not applicable" for prior authorization. No prior authorization requirement is imposed by this policy document.

Billing Rule

Coding (see above)

Coding guidance already provided above: use CPT unlisted code 64999 and include supporting documentation. Do not duplicate detailed coding instructions here.

Background and Evidence Summary

Percutaneous electrical nerve stimulation (PENS) is performed with needle electrodes inserted around or adjacent to peripheral sensory nerves in the painful area to deliver stimulation. Percutaneous neuromodulation therapy (PNT) is a variant that uses very fine filament needle-like electrode arrays placed near the painful area to stimulate peripheral sensory nerves.

Both PENS and PNT have been evaluated for chronic musculoskeletal or neuropathic pain conditions (examples include low back pain, neck pain, diabetic neuropathy, chronic headache, hyperalgesia, and knee osteoarthritis) and are intended for patients who have failed other treatments.

The highest-quality PENS trial reported no difference in outcomes between the active treatment (30 minutes of stimulation with 10 needles) and a sham procedure (5 minutes of stimulation with 2 needles).

PNT evidence includes a single randomized controlled trial that is limited by lack of investigator blinding, unclear participant blinding, and short-term follow-up. Taken together, the trial record is small and methodologically limited, and the evidence is judged insufficient to support commercial coverage.

Definitions

PENSPercutaneous electrical nerve stimulation performed with needle electrodes placed around or adjacent to nerves in the painful area.

PNTPercutaneous neuromodulation therapy using very fine needle-like/filament electrode arrays placed near the painful area; considered a variant of PENS.

Name	Number	Effective
Assessing Patient's Suitability for Electrical Nerve Stimulation	160.7.1	2006

Revision History

2018-10-02effective_date

Policy effective date.

2021-08-18last_reviewLatest

Policy last updated.

material_changeLatest

Policy differentiates Medicare Advantage (may be covered) versus Commercial (not medically necessary). Medicare Advantage coverage is aligned with CMS guidelines and PENS/PNT is covered when criteria (site, provider, and need for implantation) are met.

material_changeLatest

Commercial product position states PENS/PNT is not medically necessary due to insufficient evidence; reflects evidentiary assessment of clinical trials and limitations.

clarificationLatest

Medicare Advantage: PENS performed only in a physician's office, clinic, or hospital outpatient department and covered only when performed by a physician or incident to a physician's service; implantation of electrodes may be warranted when symptoms are effectively controlled by percutaneous stimulation.

coding_updateLatest

There is no specific code for PENS/PNT; use CPT unlisted procedure code 64999 (unlisted procedure, nervous system specific).